Add to ORKGAmongst women diagnosed with early breast cancer, the probability of recurrence and subsequent death can vary substantially depending upon a number of known prognostic factors. With such heterogeneous levels of risk, the absolute effectiveness and consequently the cost-effectiveness of adjuvant chemotherapy, a treatment known to reduce the likelihood of recurrence, can also be expected to vary between patients.EThOS - Electronic Theses Online ServiceGBUnited Kingdo
Abstract Background Due to high survival rates and th...
OBJECTIVES: To investigate the cost-effectiveness of using prognostic information to identify patien...
Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the ...
Background The risk of recurrence following surgery in women with early breast cancer varies, depen...
Background: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
• A previously published model1 was adapted for the US. The time horizon of the analysis was varied ...
Background Adjuvant chemotherapy in breast cancer patients post resection has been estimated to redu...
Background Adjuvant chemotherapy in breast cancer patients post resection has been estimated to redu...
Abstract Background Due to high survival rates and the relatively small benefit of adjuvant therapy,...
BackgroundThere remains uncertainty around the appropriate choice of adjuvant therapies to offer pos...
Abstract A Breast Cancer Outcomes model was developed at the ONCOTYROL research center...
Abstract Background Due to high survival rates and th...
Abstract Background Due to high survival rates and th...
OBJECTIVES: To investigate the cost-effectiveness of using prognostic information to identify patien...
Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the ...
Background The risk of recurrence following surgery in women with early breast cancer varies, depen...
Background: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
BACKGROUND: The risk of recurrence following surgery in women with early breast cancer varies, depen...
• A previously published model1 was adapted for the US. The time horizon of the analysis was varied ...
Background Adjuvant chemotherapy in breast cancer patients post resection has been estimated to redu...
Background Adjuvant chemotherapy in breast cancer patients post resection has been estimated to redu...
Abstract Background Due to high survival rates and the relatively small benefit of adjuvant therapy,...
BackgroundThere remains uncertainty around the appropriate choice of adjuvant therapies to offer pos...
Abstract A Breast Cancer Outcomes model was developed at the ONCOTYROL research center...
Abstract Background Due to high survival rates and th...
Abstract Background Due to high survival rates and th...
OBJECTIVES: To investigate the cost-effectiveness of using prognostic information to identify patien...
Trastuzumab (Herceptin, Roche) is a recombinant, humanized monoclonal antibody directed against the ...